INIS
adrenergics
20%
aldosterone
20%
angiotensin
40%
clinical trials
100%
cytokines
40%
diseases
40%
endothelins
20%
enzyme inhibitors
20%
heart failure
100%
hypothesis
20%
inhibition
100%
mortality
20%
patients
40%
receptors
20%
Medicine and Dentistry
ACE Inhibitor
20%
Adverse Event
20%
Adverse Outcome
20%
Aldosterone
20%
Angiotensin Receptor Antagonist
20%
Beta Adrenergic Receptor Blocking Agent
20%
Clinical Syndrome
20%
Cytokine
20%
Disease
20%
Disease Exacerbation
20%
Endothelin Receptor Antagonist
20%
Heart Failure
100%
Inpatient
40%
Introspection
100%
Mortality
20%
Proteinase
20%
Therapeutic Procedure
40%
Biochemistry, Genetics and Molecular Biology
Aldosterone
33%
Angiotensin Receptor
33%
Angiotensin-Converting Enzyme
33%
Beta Blocker
33%
Clinical Trial
100%
Cytokine
66%
Endopeptidase
33%
Endothelin
33%
Enzyme Inhibitor
33%
Introspection
100%
Mortality
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Adverse Outcome
20%
Aldosterone
20%
Angiotensin Receptor Antagonist
20%
Beta Adrenergic Receptor Blocking Agent
20%
Cytokine
20%
Cytokine Receptor Antagonist
20%
Dipeptidyl Carboxypeptidase Inhibitor
20%
Disease Exacerbation
20%
Diseases
20%
Endothelin Receptor Antagonist
20%
Heart Failure
100%
Mortality
20%
Proteinase
20%
Syndrome
20%
Neuroscience
Adverse Effect
20%
Aldosterone
20%
Angiotensin Receptor
20%
Beta Blocker
20%
Cardiovascular System
100%
Dipeptidyl Carboxypeptidase
20%
Endothelin
20%
Enzyme Inhibitor
20%
Neuroendocrine System
20%
Proteinase
20%